Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triclosan safety study

This article was originally published in The Tan Sheet

Executive Summary

"13-Week dermal subchronic toxicity study of triclosan in rats" anticipated to begin by year-end, according to the Triclosan Industry Alliance. The study is being conducted to support Category I status of the antimicrobial ingredient in the monograph for antimicrobial wash products, issued in June 1994. Under the protocol, rats will receive once daily applications for 91 days of .3 mg, 1 mg, 3 mg or 5 mg triclosan, and skin will be assessed for various endpoints. Members of the alliance include Colgate-Palmolive (Softsoap), Dial (Dial), Procter & Gamble (Safeguard), SmithKline Beecham (Oxy), Unilever (Lever 2000), Block Drug (Lava) and Ciba Specialty Chemicals. The protocol was submitted by Colgate. NDAC is meeting July 29 for discussion of product testing requirements for the antimicrobial product monograph, but is not expected to consider the triclosan protocol...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel